Our latest news

Interim Management Statement

14 November 2012

Source BioScience today provides its Interim Management Statement for the period from 1 July 2012 to 14 November 2012.

For More Information

Notification of major interest in shares

13 November 2012

The attached TR1 notification relates to Killik & Co’s shareholding in Source BioScience, which now stands at 9,465,256 shares, representing 4.6% of the Company’s ordinary share capital.

For More Information

Attendance at BioMalaysia 2012, Kuala Lumpur

24 October 2012

Senior Executives from Source BioScience are pleased to be attending BioMalaysia 2012, being held in Kuala Lumpur between 5 and 7 November, and will be located at Booth 256.

Chief Executive Officer, Dr Nick Ash and Sales Director, Dr Khosrow Shami will be on hand to discuss solutions for life science research and diagnostics requirements, as well as areas of mutual interest and collaboration.

The LifeSciences division is already a trusted and leading European provider of DNA sequencing, genomic services and bioinformatic analyses to diagnostic and research markets, including the UK National Health Service, and continues to expand its service offering and expertise in the Far East's scientific and healthcare community.

Full details of the Group's portfolio is available at www.sourcebioscience.com

Additional Listing on Exercise of Share Options

15 October 2012

Source BioScience plc announces that it has issued 1,018,034 new ordinary shares of 2 pence each in the Company (the ‘New Ordinary Shares’), representing 0.50% of its enlarged issued share capital, following the election by certain option holders to exercise options under the Source BioScience Group plc Share Option Schemes.

For More Information

Notification of major interest in shares

05 October 2012

The attached TR1 notification relates to Standard Life Investment Ltd's shareholding in Source BioScience, which now stands at 9,500,000 shares, representing 4.662% of the Company’s ordinary share capital.

For More Information

Notification of major interest in shares

03 October 2012

The attached TR1 notification relates to Swedbank Robur Fonder AB’s shareholding in Source BioScience, which now stands at 6,000,000 shares, representing 2.94% of the Company’s ordinary share capital.

For More Information